62nd ERA Congress

Publication

ERA •
6 June, 2025 •
•

Pegcetacoplan demonstrates clinically significant responses in C3G and Primary (Idiopathic) IC-MPGN patients with or without concomitant immunosuppression in VALIANT

David Kavanagh, Andrew S Bomback, Gema Ariceta, Antonio Mastrangelo, Carla M Nester, Giuseppe Remuzzi, Marina Vivarelli, Zhongshen Wang, Johan Szamosi, Dima Decker, Lucía Quintana-Gallardo, Fadi Fakhouri

Available materials

Oral Presentation

Publication

ERA •
6 June, 2025 •
•

Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or Primary (Idiopathic) IC-MPGN

Marina Vivarelli, Andrew S Bomback, Gema Ariceta, Antonio Mastrangelo, Carla M Nester, Giuseppe Remuzzi, Nicole Van De Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lucía Quintana-Gallardo, Fadi Fakhouri

Available materials

Oral Presentation

Publication

ERA •
6 June, 2025 •
•

Targeted treatment with pegcetacoplan for adolescents with C3G or Primary (Idiopathic) IC-MPGN in the VALIANT phase 3 trial

Antonio Mastrangelo, Marina Vivarelli, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Christoph Licht, Nabil Melhem, Nicole Van De Kar, Dean Wallace, Li Li, Luis López Lázaro, Carla M Nester

Available materials

Oral Presentation

Publication

ERA •
6 June, 2025 •
•

Pegcetacoplan treatment appears to halt disease progression in C3G and Primary (Idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study

Daniel P Gale, Andrew S Bomback, Christoph Licht, Carla M Nester, Matthew C Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lucía Quintana-Gallardo, Fadi Fakhouri

Available materials

Poster

Publication

ERA •
6 June, 2025 •
•

Targeted treatment with pegcetacoplan for post-transplant recurrent C3G or Primary (idiopathic) IC-MPGN in the VALIANT phase 3 trial

Michiel Oosterveld, Jessica Kaufeld, Daniel Zecher, Kathleen Klaas, Julien Zuber, Irene Noronha, Andrew S Bomback, Zhongshen Wang, Johan Szamosi, Li Li, Luis López Lázaro, Ondrej Vicklicky

Available materials

Poster

Publication

ERA •
6 June, 2025 •
•

Association between proteinuria and clinically meaningful endpoints in patients with C3G / IC-MPGN: a Delphi consensus of European experts

Fernando Caravaca-Fontán, Matthew C Pickering, Edwin Wong, Fadi Fakhouri, Christoph Licht, Marina Vivarelli, Franz Schaefer

Available materials

Poster

Publication

ERA •
6 June, 2025 •
•

Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy

Fadi Fakhouri, Gema Ariceta, Andrew S Bomback, Bradley P Dixon, Moglie Le Quintrec, Antonio Mastrangelo, Matthew C Pickering, Giuseppe Remuzzi, Nicole CAJ Van de Kar, Marina Vivarelli, Daniel Zecher, Carla M Nester

Available materials

Oral Presentation

Symposium

ERA •
6 June, 2025 •
•

Cracking the Complement Sequence

Marina Vivarelli, Matthew C Pickering, Fadi Fakhouri

Available materials

Slides

Publication

ERA •
5 June, 2025 •
•

A thematic analysis of healthcare provider perspectives on the care pathway and unmet needs in C3G and primary IC-MPGN in the US and Europe

Carly Rich, Elizabeth A Holdsworth, Sarah Clayton, Mona Amet, Laura Mirams, Ryan Naylor, Mingyi Huang, Katie Gordon, Lucía Quintana-Gallardo

Available materials

Poster

Medical materials